The following stocks had recent and notable activity in their options: $EXAS (7/29): 8,000 OCT 20.0 Strike Calls were sold (stock at $15.78) for 0.50 or total proceeds of $400,000 against a 800,000 share position (this was a covered Call). Trade provides $0.50 of protection to the downside (and takes position out above $20). $DEPO […]
Catalyst Watch – Vol. 2, Edition 23 (7/29/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: I continue […]
Catalyst Watch – Vol. 2, Edition 22 (7/7/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates AEZS: I’m […]
Catalyst Watch – Vol. 2, Edition 21 (6/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates MNKD: PDUFA […]
Catalyst Watch – Vol. 2, Edition 20 (6/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates No updates […]
Catalyst Watch – Vol. 2, Edition 19 (6/13/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates CNAT: Holding […]
Catalyst Watch – Vol. 2, Edition 18 (6/3/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: As […]
Catalyst Watch – Vol. 2, Edition 17 (5/29/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates DRTX: Dalvance […]
Catalyst Watch – Vol. 2, Edition 16 (5/22/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: I […]
Catalyst Watch – Vol. 2, Edition 15 (5/15/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: Updates […]
Catalyst Watch – Vol. 2, Edition 14 (5/8/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: AEZS: […]
Catalyst Watch – Vol. 2, Edition 13 (5/2/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: Changes […]
Catalyst Watch – Vol. 2, Edition 12 (4/18/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: Changes […]
High Cash / Share Stocks in Biotech (Part I)
Due to the sector sell-off in biotech, I thought it may be interesting to provide subscribers a list of high net cash per share stocks (basically cash and equivalents less debt divided by fully diluted shares outstanding). I think this metric is quite useful and (at times – not always) allows one to gauge risk […]
Catalyst Watch – Vol. 2, Edition 11 (4/11/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Catalyst Watch – Vol. 2, Edition 10 (4/4/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Catalyst Watch – Vol. 2, Edition 9 (3/28/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Catalyst Watch – Vol. 2, Edition 8 (3/18/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Catalyst Watch – Vol. 2, Edition 7 (3/12/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Week’s Option Activity (2/20 ~ 3/04)
The following stocks had notable activity in their options during the past week(s): $CYTK (2/20): There were two large trades – one bullish and one bearish. (1) Bullish: 2,900 MAY risk reversals were purchased (stock at $9.85) for net 1.10 or total net cost of $319,000 (2,900 MAY 7.50 Strike Puts were sold for 1.90 […]
